ZPHC Semaglutide AQ pen 6 mg

Semaglutide (Ozempic, Wegovy) AQ pen – 6 mg — Weight loss support

This FDA-approved medicine works on GLP-1 pathways to reduce hunger, increase fullness, and boost metabolism—leading to meaningful weight loss.

How it works

GLP-1 action: Reduces appetite, increases satiety, and enhances metabolic control for clinically significant weight loss.

Your dosing schedule

• Start: 0.25 mg per week to minimize stomach upset
• Target: 0.25–2.4 mg per week (individual titration)
• Treatment length: 16–68 weeks, depending on your response

How to take it: One injection under the skin, once a week. Follow sterile technique and storage instructions.

What to expect

Common side effects: Nausea, vomiting, diarrhea, constipation, reduced appetite. Usually improve as your body adjusts. Eat small meals and stay hydrated.

Serious (rare): Severe belly pain, gallbladder problems, fast heartbeat. Stop immediately and contact your doctor.

Not for you if: Pregnant, breastfeeding, or have medullary thyroid cancer or MEN2 history.

Getting started

• Medical review — Confirm it’s safe and right for you
• Baseline tests — Weight, blood sugar, and other labs
• Ongoing support — Regular check-ins, dose adjustments, and lifestyle guidance

We recommend using a peptide dosage and reconstitution calculator to determine how many pens you’ll need for your cycle.